Folate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth
Preprint
Abstract
Tumor-associated macrophages (TAMs) promote tumor progression, inhibit anti-tumor immunity, and induce resistance to immune checkpoint inhibitors (ICI). Metabolism is a primary determinant of TAM polarization, suggesting therapies that selectively modulate TAM metabolic state may hold therapeutic benefit. Here we demonstrate folate uptake and metabolism sustained by the myeloid-restricted folate receptor beta (FRβ) are critical for TAM immunosuppressive function. Folate was depleted in the microenvironment of human melanomas, suggesting FRβ upregulation by TAMs may be an adaptive response to folate scarcity. FRβ⁺ TAMs exhibited an immunosuppressive phenotype and were associated with immunotherapy resistance in melanoma patients. Genetic ablation of FRβ attenuated tumor growth across multiple cancer models and repolarized macrophages toward pro-inflammatory states, promoting tumor infiltration by activated lymphocytes. Critically, excess folate reversed the phenotypes observed with FRβ loss, suggesting these effects stem from impaired folate uptake by TAMs rather than a folate-independent role for FRβ. Integrated metabolomic, transcriptomic, and functional mechanistic studies demonstrated that folate acquisition via FRβ was required to generate reduced glutathione to limit mitochondrial reactive oxygen species (ROS) production. In the absence of FRβ, mitochondrial oxidative stress promoted canonical NF-kB signaling and macrophage pro-inflammatory polarization. Thus, FRβ couples a nutrient-limited microenvironment to TAM immunosuppressive function and represents a therapeutically tractable metabolic checkpoint for TAMs.Keywords
Funding Information
- NIGMS (T32 GM133364)
- American Society of Hematology
- James and Jesse Millis Distinguished Professorship of Surgery
- NCI (R01CA236910)
- NCI (R37CA251877)
- NCI (P50CA257911)
- Pancreatic Cancer Action Network (22-WG-DERB)
- Burroughs Wellcome Fund (Career Award for Medical Scientists)
- NIH (K08CA248960)
- V Foundation for Cancer Research (V Scholar Award)
- Melanoma Research Alliance (Young Investigator Award)
- University Cancer Research Fund
This publication has 54 references indexed in Scilit:
- Utility of [99mTc]Tc-tilmanocept, an immunosuppressive macrophage functional imaging agent in melanoma patients receiving checkpoint inhibitor treatment: a feasibility studyCancer Immunology, Immunotherapy, 2025
- ZEB2 is a master switch controlling the tumor-associated macrophage programCancer Cell, 2025
- A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanomaCell, 2024
- Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancerCell, 2022
- Serine Catabolism Feeds NADH when Respiration Is ImpairedCell Metabolism, 2020
- Serine Metabolism Supports Macrophage IL-1β ProductionCell Metabolism, 2019
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- One-Carbon Metabolism in Health and DiseaseCell Metabolism, 2017
- Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor βCancer Immunology, Immunotherapy, 2009
- Mitochondrial ROS-induced ROS release: An update and reviewBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2006